Zydus Cadila gets USFDA approval for Esomeprazole Magnesium delayed-release capsules

The company said Esomeprazole belongs to the group of medicines termed as proton pump inhibitors.

New Delhi: Zydus Cadila has received final approval from the US health regulator to market Esomeprazole Magnesium delayed-release capsules, used to treat acid reflux. The approval has been granted in the strengths of 25 mg and 40 mg, the company said in a BSE filing.

Zydus Cadila said the drug will be produced at the group's formulations manufacturing facility at Ahmedabad.

The company said Esomeprazole belongs to the group of medicines termed as proton pump inhibitors.

Also Read: Zydus Cadila gets USFDA nod for Chlorthalidone tablets to treat high BP

Esomeprazole reduces the amount of acid secreted by the stomach.

The group has more than 266 approvals and so far filed over 350 abbreviated new drug applications (ANDAs) since it started filings in 2003-04.

Also Read: CDSCO approves Zydus, SIFI pact to launch Intraocular Lenses in India